Longitudinal Early-onset Alzheimer's Disease Study Protocol

Status: Recruiting
Location: See all (23) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 64
Healthy Volunteers: t
View:

• Meets NIA-AA criteria for MCI due to AD or probable AD dementia

• Have a global CDR score ≤ 1.0

• Have capacity to provide informed consent (IC) or has a legal authorized representative or guardian who provides IC

• Age between 40-64 years (inclusive) at the time of consent

• Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, caregiver) who is generally aware of the participants' daily activities and can provide information about the participant's cognitive and functional performance. If the participant does not have a study partner who spends at least 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the Site PI

• Willing and able to complete longitudinal study procedures aside from LP which is an optional procedure

• Not pregnant or lactating. Women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each PET scan

• Fluent in English or Spanish if enrolled in the U.S.

• Fluent in English, Spanish, Dutch or Swedish for sites outside the U.S., according to site's spoken language(s).

• Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living

• Have a global CDR score = 0

• Have capacity to provide informed consent

• Have a Mini-Mental State Exam score between 26-30 (inclusive). Exceptions may be made for participant with less than 8 years of education at the discretion of the Site PI

• Age between 40-64 years (inclusive) at the time of consent

• Must have a study partner (informant) who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, caregiver) who is generally aware of the participants' daily activities and can provide information about the participant's cognitive and functional performance. If the participant does not have a study partner who spends 10 face-to-face hours per week, other arrangements for identifying a viable study partner will be granted on a case-by-case basis by the Site PI

• Willing and able to complete longitudinal study procedures aside from LP which is an optional procedure

• Not pregnant or lactating. Women must be two years post-menopausal, be surgically sterile, or have a negative pregnancy test prior to each PET scan

• Fluent in English or Spanish if enrolled in the U.S.

⁃ Fluent in English, Spanish, Dutch or Swedish for sites outside the U.S., according to site's spoken language(s).

Locations
United States
Arizona
Banner Sun Health Research Institute
RECRUITING
Sun City
California
University of California, Los Angeles
RECRUITING
Los Angeles
Stanford University
RECRUITING
Palo Alto
University of California, San Francisco
RECRUITING
San Francisco
Washington, D.c.
Georgetown University
RECRUITING
Washington D.c.
Florida
Mayo Clinic, Jacksonville
RECRUITING
Jacksonville
Wien Center
RECRUITING
Miami Beach
Georgia
Emory University
RECRUITING
Atlanta
Illinois
Northwestern University
RECRUITING
Chicago
Indiana
Indiana University
RECRUITING
Indianapolis
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Maryland
Johns Hopkins University
RECRUITING
Baltimore
Minnesota
Mayo Clinic, Rochester
RECRUITING
Rochester
Missouri
Washington University, St. Louis
RECRUITING
St Louis
New York
Columbia University
RECRUITING
New York
Pennsylvania
University of Pennsylvania
RECRUITING
Philadelphia
Rhode Island
Butler Hospital
RECRUITING
Providence
Texas
Houston Methodist Hospital
RECRUITING
Houston
Other Locations
Argentina
Fleni
NOT_YET_RECRUITING
Buenos Aires
Netherlands
Amsterdam UMC
NOT_YET_RECRUITING
Amsterdam
Spain
Hospital de la Santa Creu i Sant Pau
NOT_YET_RECRUITING
Barcelona
Sweden
Lund University
NOT_YET_RECRUITING
Malmo
United Kingdom
University College London
NOT_YET_RECRUITING
London
Contact Information
Primary
IU LEADS Team
iuLEADS@iupui.edu
317-963-7436
Time Frame
Start Date: 2018-04-30
Estimated Completion Date: 2026-05-31
Participants
Target number of participants: 850
Treatments
Early Onset Alzheimer's Disease (EOAD)
* Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~* Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)~* CDR score ≤ 1.0~* flortaucipir (18F-AV-1451) PET scanning
Cognitively Normal (CN) Controls
* Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living~* Mini-Mental State Exam score between 26-30~* CDR score = 0~* flortaucipir (18F-AV-1451) PET scanning
Early Onset non-Alzheimer's Disease (EOnonAD)
* Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~* Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)~* CDR score ≤ 1.0~* flortaucipir (18F-AV-1451) PET scanning
Sponsors
Collaborators: Alzheimer's Association, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA)
Leads: Indiana University

This content was sourced from clinicaltrials.gov